Neurology Department, Fundeni Clinical Institute, Bucharest; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Carol Davila University of Medicine and Pharmacy, Bucharest; Gastroenterology and Hepatology Department, Fundeni Clinical Institute, Bucharest, Romania.
J Gastrointestin Liver Dis. 2024 Sep 29;33(3):355-361. doi: 10.15403/jgld-5231.
Minimal hepatic encephalopathy (MHE) represents the mildest form of hepatic encephalopathy. MHE has been associated with impairment of quality of life and job performance, and is a major cause of premature retiring in cirrhotic patients. However, MHE is usually overlooked by most physicians, due to its asymptomatic nature. We aim to present our experience with the EncephalApp Stroop Test for diagnosing MHE in cirrhotic patients. We also want to establish if Stroop test performance correlates with age, educational level, liver disease severity (as assessed by the MELD and Child-Pugh scores), duration of disease, previous episodes of overt hepatic encephalopathy, and other relevant clinical or laboratory parameters.
A cross-sectional observational single-center study, in which 100 adult patients diagnosed with liver cirrhosis were evaluated for the presence of MHE by using the EncephalApp Stroop Test. In parallel, 45 healthy adult controls without liver cirrhosis were recruited and tested under the same conditions as the patients.
There were no age-related differences between the two groups (p=0.6). Stroop test performance of the controls (143.1 ± 20.8 seconds) was significantly better than that of the patients (171.9 ± 33.3 seconds) (p<0.0001). Stroop test results correlated with the MELD (R=0.28, p=0.005) and Child-Pugh scores (R=0.2, p=0.04). There was a positive correlation between Stroop test results and age in patients (R=0.45, p<0.0001) and controls (R=0.75, p<0.0001). Stroop test performance was not influenced by the duration of liver disease (p=0.4) or prior episodes of overt hepatic encephalopathy (p=0.25). Gender and level of education did not have an impact on Stroop test results. Alcoholic liver disease, diabetes mellitus, hyperglycemia, anemia and hyponatremia were associated with poorer performances.
EncephalApp Stroop Test proved to be a quick and simple method for diagnosing minimal hepatic encephalopathy in the hospital setting. Test performance was influenced primarily by age, but also by liver disease severity, anemia, hyponatremia and hyperglycemia.
轻微型肝性脑病(MHE)是肝性脑病最轻微的形式。MHE 与生活质量和工作表现受损有关,是肝硬化患者提前退休的主要原因。然而,由于其无症状性质,大多数医生通常会忽略 MHE。我们旨在介绍我们使用 EncephalApp Stroop 测试诊断肝硬化患者 MHE 的经验。我们还想确定 Stroop 测试表现是否与年龄、教育水平、肝脏疾病严重程度(通过 MELD 和 Child-Pugh 评分评估)、疾病持续时间、先前显性肝性脑病发作以及其他相关临床或实验室参数相关。
这是一项横断面观察性单中心研究,其中评估了 100 名成年肝硬化患者是否存在 MHE,使用了 EncephalApp Stroop 测试。同时,招募了 45 名没有肝硬化的健康成年对照者,并在与患者相同的条件下进行测试。
两组之间没有年龄相关的差异(p=0.6)。对照组的 Stroop 测试表现(143.1 ± 20.8 秒)明显优于患者(171.9 ± 33.3 秒)(p<0.0001)。Stroop 测试结果与 MELD(R=0.28,p=0.005)和 Child-Pugh 评分(R=0.2,p=0.04)相关。患者的 Stroop 测试结果与年龄呈正相关(R=0.45,p<0.0001)和对照组(R=0.75,p<0.0001)。Stroop 测试表现不受肝脏疾病持续时间(p=0.4)或先前显性肝性脑病发作的影响(p=0.25)。性别和教育水平对 Stroop 测试结果没有影响。酒精性肝病、糖尿病、高血糖、贫血和低钠血症与较差的表现相关。
EncephalApp Stroop 测试被证明是一种在医院环境中快速简便的诊断轻微型肝性脑病的方法。测试表现主要受年龄影响,但也受肝脏疾病严重程度、贫血、低钠血症和高血糖影响。